Nanotoxicity of Corona-Nanoparticles (SARS-COV-2): Nanomechanisms of Hypoxia

Amel Hanini\textsuperscript{1,2*}, Ouajdi Souilem\textsuperscript{2} and Hafedh Abdelmelek\textsuperscript{1}

\textsuperscript{1}Laboratoire de Physiologie Intégrée, Faculté des Sciences de Bizerte, Université de Carthage, Jarzouna, Tunisia
\textsuperscript{2}Laboratoire de Valorisation des Bio-Géo-Resources, Ecole Nationale de Médecine Vétérinaire de Sidi Thabet, Université de la Manouba, Sidi Thabet, Tunisia

*Corresponding author:
Dr. Amel Hanini, Université de Carthage, Faculté des Sciences de Bizerte, Jarzouna, Tunisia, E-mail: Hafedh.abdelmelek@fsb.rnu.tn

Received: 29 June 2020
Accepted: 22 July 2020
Published: 27 July 2020

Citation:
Hanini A, Souilem O, Abdelmelek H. Nanotoxicity of corona-nanoparticles (SARS-COV-2): Nanomechanisms of hypoxia. J Nano Res Adv Mater Polym Sci. 2020;1:05.

Abstract

The present review aims to help the scientific community to better understand, \textit{in vitro} and \textit{in vivo}, COVID-19 compared to Monge disease (MD). The SARS-COV-2 or Corona-nanoparticles (NPs: 60-140nm) model based on nanosciences give an innovative understanding of virus nanotoxicity associated with violent inflammatory reactions and acute respiratory distress. Our analysis of COVID-19 suggests for the first time as far as we know that SARS-COV-2 use nanosciences laws such as virus agglomeration and mitochondria respiration toxicity induced by cluster virus-Heme. Moreover, the implication of age, gender, and ethnicity to COVID-19 must be confirmed by future studies compared to MD. The virus could use nano mechanisms to induce hypoxia via the generation of Heme-virus clusters mitigating micro coagulation implicated in acute respiratory distress and heart failure. Our analysis points to the presence of a possible link between hypoxia and COVID-19 pro-pulmonary complications.

Keywords: SARS-COV-2, COVID-19, Monge Disease, Chloroquine, Nanotoxicity.
Introduction

Until now in the field of virology and Nanomedicine, viral diseases related to COVID-19 (Coronavirus disease 2019) can be considered as a mystery to their unusual mechanism of pathogenicity. Take anything you learned in the field of epidemiology, especially about recent viral diseases, and throw it out the door because COVID-19 are exceptional and probably the only pathology with this exceptional physiopathology and leading to important lethality(1). Recently, huge controversy related to the use of different drugs such as Hydroxychloroquine and Chloroquine against COVID-19(2). In the absence of specific COVID-19 treatment or vaccination, this drug protocol is the most hotly discussed issue in molecular-cellular toxicity and therapeutic of these molecules (3). For all these considerations we propose a new interpretation based on Nanosciences, physiology, physiopathology, and Nano-pharmacology on SARS-COV-2 cytopathogeny as nanoparticles (NPs). NPs cytotoxicities are related to several physicochemical properties such as concentration, size, up-take mechanism(4). The toxicity of Co-ferrite oxide NPs may be attributed either to their direct uptake by cells or to their dissolution leading to the increased level of cationic ions in the growth media and/or inside the cells. Focusing on cobalt-ferrite NPs, literature remains controversial where some findings show in vitro and in vivo toxicities and others found that Co- Superparamagnetic Iron Oxide Nanoparticles (SPIONs) are not cytotoxic. Different types of SPIONs, varying in their composition and/or surface coating, can be synthesized, depending on the requirements for their application(5,6).

Properties of Corona-nanoparticles (SARS-COV-2)

The present review provides a detailed overview of NPs properties. NPs are tiny materials having size ranges from 1 to 100nm such as Covid-19 having a diameter of approximately 60–140 nm(3). Recently in 2020, the structure of the virus in the cytoplasm of three-day post-inoculation cells was examined by electron microscopy; showing that virus particle size ranged from 70–90 nm and the virus was observed in a wide range of intracellular organelles, especially in vesicles(7). Coronaviruses are enveloped and have single-stranded positive-sense RNA genomes. A coronavirus particle consists of four structural proteins: the nucleocapsid, envelope, membrane, and spike. The Spike (S) protein (about 20nm) forms club-shaped protrusions that stick out all over the virion, resembling a crown or the sun’s corona. Transmission of the virus is usually via airborne droplets (>5000nm) to the nasal mucosa and contaminated surfaces. SARS-CoV-2 attacks human angiotensin-converting enzyme 2 (ACE-2) in numerous tissues especially ciliated bronchial, epithelial cells, and type II pneumocytes. Moreover, SARS-CoV-2 infection induces atypical pneumonia associated with high levels of pro-inflammatory cytokines. SARS-COV-2 NPs possess unique physical and chemical properties due to their high surface (S) area compared to volume (V) (S/V ratio) and Nanoscale size directly or indirectly implicated in the different biological processes such as inflammation independently of classic immunological reactions. Interestingly, nanotechnology could be developed in physico-chemistry Labs or living systems (Bottom-up approaches) as viral replication in cells by bioengineering Nano mechanisms.

Nanotoxicology has demonstrated that physic-chemical properties of NPs including size, shape, surface coating, surface charge, solubility, and chemical composition could dramatically affect Corona-NPs behavior in biological systems and thus modulate Human and Animal toxicity in blood and tissues. In
nanosciences, the uncoated-NPs (U-NPs) agglomerate with chemical and physical laws in the environment and organs(4,8). The investigation of the Physico-chemical characteristics and their impact on the biological effects of Corona-NPs is important to better understand their pneumotoxic mechanism. We discuss a new model based on the concept of induction of COVID-19 by a simple conversion of uncoated SARS-COV-2 or corona-NPs (U-NPs) to coated NPs (C-NPs), which is a normal form of virus implicated in the bioengineering of the virus known as a viral cycle. The U-NPs (SARS-COV-2) agglomerate with chemical and physical Also, drugs (such as Hydroxychloroquine and Chloroquine) are proposed to be used for COVID-19 therapy but the mechanism of action of this drug against SARS-COV-2 is still unknown. Both drugs have a flat aromatic core structure at nano-scale levels. The basic side chain is thought to contribute to the accumulation of these drugs in intracellular compartments, especially lysosomal compartments. Interestingly, the anti-inflammatory effects of hydroxychloroquine and chloroquine could be explained by the inhibition of lysosomal activity.

**Nanotoxicological interpretation of cellular and molecular nanomechanisms of hypoxia induced by SARS-COV-2**

A key pathological feature of SARS-Cov-2 NPs is hypoxia that could be analyzed or compared to pseudo-Monge disease. Hypoxia can be considered as a failure of oxygen supply to maintain tissue ATP production. The normal alveolar Po2 (~ 110 mm Hg) is high than other organs in which oxygen tension ranges from 3–20 mm Hg(9).

Acute respiratory distress is a severe form of hypoxic disease responsible for a large number of deaths worldwide induced by SARS-COV-2. New strategies are urgently required to help scientists to understand SARS-Cov-2 nanotoxicity and to design innovative therapies. We will review recent advances in our understanding of COVID-19 disease and the physiopathology of direct or indirect hypoxia. The direct hypoxia is related to alveolar alteration of oxygen supply and indirect hypoxia is linked to disruption of oxygen transport via erythrocytes. Comparative physiology or physiopathology of acute respiratory distress between COVID-19 to Monge Disease may provide new insights into the implication of nano mechanisms of cellular interactions between erythrocyte (70000 nm) and virus (60-140nm). Hypoxia in COVID-19 as in Monge Disease induced organ ischemia and inflammatory process(9,10).

In both diseases, the hypoxia-induced inflammatory response results in the recruitment of immune cells, the activation of downstream signaling pathways, and the induction of pro-inflammatory cytokines and chemokines. In addition, these extremely low concentrations of oxygen prolong neutrophil survival and increase endothelial permeability and vascular leakage. Interestingly, the mechanisms of hypoxic responses have been extensively investigated in animal models in vivo, where hypoxic-ischemic conditions are typically induced by vascular occlusion, and in vitro models in which oxygen has been reduced to 0.5–1.0%, mimicking the oxygen concentrations encountered during ischemia. The first to be identified as the hypoxia-inducible factor (HIF) family, which response in a rapid manner to profound reductions in cellular oxygen concentration(9).

At high altitude, hypertension induces right heart failure and death in susceptible individuals, as seen in Monge disease. Moderate alveolar hypoxia, high altitude, provokes an increase of macrophages, neutrophils, and inflammatory cytokines, including IL-1β, IL-6, IL-8, and TNF-α, in human bronchoalveolar lavage fluid. Similarly, rodents exposed to alveolar hypoxia demonstrate a pulmonary infiltration of neutrophils,
macrophage associated with increased pulmonary vascular permeability and elevations of inflammatory cytokines in the lung. The comparative physiopathology of hypoxia demonstrates in human and animal inflammatory pulmonary lesions(9).

The SARS-COV-2 as nanoparticles could induce mitochondria toxicity indirectly induced by iron released from Heme or a different cluster Fe-S between virus and Heme activating Fenton reaction (Figure 1). Interestingly, mitochondria are considered a major cell compartment relevant to possible SARS-COV-2 nanoparticle toxicity. Impairment of mitochondria might be a key problem since mitochondrial dysfunction may result in reduced cellular ATP delivery, increased reactive oxygen species production, and triggering of apoptosis pathways. Accordingly, mitochondrial dysfunctions occur early in many acute or chronic diseases such as peripheral arterial or pulmonary diseases. Mitochondrial involvement in SPIONs toxicity remains controversial and either no deleterious effects or mitochondrial impairments have been observed. Baratli et al.(11) reported that age-dependent accumulation of mitochondrial iron or other nanoparticles (like cluster Heme Fe-S: virus) may increase mitochondrial dysfunction and oxidative damage, thereby enhancing the susceptibility to apoptosis. Therefore, age might modify the susceptibility of mitochondria to iron nanoparticles (NPs). Since, to date, few studies investigated the potential effects of iron oxide nanoparticles on middle-aged mitochondria. Our previous investigation compared the effects of three different concentrations of Fe3O4 nanoparticles (250, 300, and 350 μg/mL) on young and middle-aged liver mitochondrial respiratory chain complexes activities and mitochondrial coupling of phosphorylation to oxidation, showing that, unlike young animals, middle-aged rats are sensitive to iron oxide nanoparticles. Indeed, liver mitochondrial respiration chain complexes I, II, III, and IV activities are altered by Fe3O4 NPs. Further, 250, 300, and 350 μg/mL of Fe3O4 specifically impair liver mitochondrial coupling in middle-aged rats. The fragility of mitochondria seems to increase in function of age. Also, aging induces loss of mitochondrial function in rodents and monkeys. In mitochondria, the iron complex probably induced Fenton reaction with endogenous H2O2 to produce the highly reactive ˙OH radical. Meanwhile, the continuous production of ˙OH is toxic to cells because it depolarizes the mitochondrial membrane potential, blocking the cell cycle in different organs such as the lung, heart, kidneys, and brain(11). These results establish a new system for Fe-mediated ˙OH generation via intra-mitochondrial Fenton reaction in response to the microenvironment of hypoxia in different tissues, which opens promising research and therapeutic roots against COVID-19. In COVID-19, some patients probably develop severe hypoxemia due to evident nanocluster virus-Heme interaction and trigger excessive erythrocyte production associated with high level of hemoglobin and hematocrit (Figure 1).
Figure 1: Acute respiratory distress physiopathology in COVID-19.

SARS-COV-2 (NPs: 60-140nm) → ACE2 → Violent inflammation induced by nanovirus

Virus S/V: biological reactivity related to high surface (S). Volume (V)

Lung → Pulmonary alveolar → Cluster Virus-Heme

Cluster in Microvasculature and in mitochondria in Lung, heart, brain, kidneys…etc

Blood → Hypoxia → Ischemia → Acute Respiratory Distress & Heart Failure
COVID-19 could be considered in part as Pseudo-Monge Disease

Monge’s disease (MD) is a progressive incapacitating syndrome caused by long term exposure to hypoxia. MD is characterized by severe erythrocytosis (SE; women hemoglobin Hb ≥19 g/dL, mean Hb ≥21 g/dL) inducing hypoxia and pulmonary hypertension leading to cor-pulmonale and congestive heart failure. In sum, there is a need for appropriate and innovative medical information and interpretations of hypoxic diseases to provide adequate physiopathology mechanisms of COVID-19.

The purpose of this analysis is to address comparative physiopathology and nano mechanisms of hypoxia in MD and COVID-19. In altitude, Human physiology hypoxia is known as a deviation above the mean Hb concentration(9). Interestingly, a recent study by Cao et al.(12) points out that ACE2 expression analysis in lung tissues from Asian and Caucasian populations is still controversial. Moreover, molecular analysis of single-cell RNA-sequences revealed that the Asian donor had a higher ACE2 expression cell ratio than African-American and white donors. Besides, the physiological adaptation of people to altitude and hypoxia was different between women and men. In the same way, native Ethiopians are more adapted than Andeans and Han immigrants(13). This adaptation is reflected essentially in a lower Hb concentration, and therefore in a lower prevalence of SE and MD. While, the lowest values are found in Tibetans (Qinghai-China) with a MD prevalence of about 1.21%; compared to Han immigrants (5.60%) in the same city(14). In the Andes, the highest values of prevalence were about 15.40% in men (30-39 years) and increased by 33% (about 60 years)(9).

Interestingly, acute respiratory distress and a large number of deaths induced by altitude or SARS-COV-2 are the most important facts of MD and COVID-19. These observations must be validated in COVID-19 patients from different ages, gender, and ethnics as previously demonstrated in MD. At a similar altitude and using the same diagnostic criteria, this variability could be attributed mainly to differences in ethnicity. People living longer time at high altitude probably is more likely to be better adapted to hypoxia. The question is whether people living at high altitudes react to COVID-19 and by the way, we can explain the discrepancy of death recently reported in the USA with COVID-19 black patients compared to other American citizens (Figure 1).

Taken together, the scientist must compare different symptoms in COVID-19 with MD. The most important symptoms observed in MD are sleep disturbances, headache, lack of mental concentration, loss of appetite, fatigue, breathlessness and/or palpitations, localized cyanosis, dilatation of veins, and muscle and joint pain. In addition, in MD radiographic examination reveals right-ventricular hypertrophy. Interestingly, an autopsy of MD patients reported generalized brain and visceral congestion(15).

The most important MD symptom is the loss of human or animal ventilatory acclimatization to altitude and recently observed in COVID-19. Evidence at different levels suggests a genetic basis for SE associated with age, gender, ethnicity, and pathologies such as obesity that could enhance directly or indirectly tissues inflammations. In MD and probably in COVID-19, the lack of respiratory sensitivity to hypoxia and hypoventilation is observed in advanced age, male gender, and overweight are all risk factors(16).

In this context, several pharmacological approaches have shown promising results in the treatment of SE and MD such as ACE inhibitors, dopaminergic antagonists, acetazolamide and ventilatory stimulants.
(medroxyprogesterone) and almitrine. Thus, we propose COVID-19 treatment based on acetazolamide(17-19).

Conclusion

Our analysis of COVID-19 suggests for the first time as far as we know that SARS-COV-2 as nanoparticles inducing agglomeration, violent inflammation, and mitochondria respiration toxicity. Moreover, SARS-COV-2 provokes many similar symptoms previously observed in MD such as acute respiratory distress. The implication of age, gender, overweight, and ethnicity to COVID-19 must be confirmed by future studies compared to MD. Virus could use nano mechanisms to induce hypoxia via the generation of Heme-virus clusters mitigating microcoagulation. The most important question is whether patients living at high altitudes and adapted to hypoxia will have different nano mechanisms against SARS-COV-2 compared to normoxic patients.

References

1. Carlo, Mariachiara Di Nuzzo, Nicole Barp, et al. Coronavirus Pandemic The novel zoonotic COVID-19 pandemic: An expected global health concern. J Infect Dev Ctries 2020;14:254-264.
2. Dogar, M. U. et al. Hydroxychloroquine-induced restrictive cardiomyopathy: a case report. Postgrad. Med. J 2018;94:185–186.
3. Cascella M, Rajnik M, Cuomo A, et al. Features, Evaluation and Treatment Coronavirus (COVID-19). StatPearls, Treasure Island 2020.
4. Hanini A, Schmitt A, Kacem K, et al. Evaluation of iron oxide nanoparticle biocompatibility. Int J Nanomedicine 2011;6:787-794.
5. Mahmoudi, M., Laurent, S., Shokrgozar, M.A., et al. Toxicity evaluations 13 of superparamagnetic iron oxide nanoparticles: cell "vision" versus physicochemical 14 properties of nanoparticles. ACS Nano 2011;5:7263-7276.
6. Baratli Y, A. L Charles, V. Wolff, L. Ben Tahar, L. Smiri, J. Bouitbir, J. Zoll, F. Piquard, O. Tebourbi, M. Sakly, H. Abdelmelek, and B. Geny, “Impact of iron oxide nanoparticles on brain, heart, lung, liver and kidneys mitochondrial respiratory chain complexes activities and coupling,” Toxicol In Vitro, 2013;27:pp.2142-2148.
7. Jeong-Min Kim, a Yoon-Seok Chung, a Hye Jun Jo, et al. Identification of Coronavirus Isolated from a Patient in Korea with COVID-19Osong Public Health Res Perspect. Feb 2020;11:3–7.
8. Ferchichi S, Trabelsi H, Azzouz I, et al. Evaluation of oxidative response and tissular damage in rat lungs exposed to silica-coated gold nanoparticles under static magnetic fields. Int J Nanomedicine 2016;11:2711-2719.
9. Monge C, León-Velarde F, Arregui A. Increasing prevalence of excessive erythrocytosis with age among healthy high-altitude miners. N Engl J Med. 1989;321:1271.
10. Ding Y, He L, Zhang Q, et al. Organ distribution of severe acute respiratory syndrome(SARS) associated coronavirus(SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways. The Journal of Pathology 2004;203:622–630.
11. Baratli Y, Charles AL, Wolff V, Ben Tahar L, Smiri L, Bouitbir J, Zoll J, Sakly M, Auger C, Vogel T, Abdelmelek H, Tebourbi O, Geny B.Age modulates Fe3O4 nanoparticles liver toxicity: dose-
dependent decrease in mitochondrial respiratory chain complexes activities and coupling in middle-aged as compared to young rats. Biomed Res Int. 2014:474081.

12. Cao DY, Spivia WR, Veiras LC, Khan Z, Peng Z, Jones AE, Bernstein EA, Saito S, Okwan-Duodu D, Parker SJ, Giani JF, Divakaruni AS, Van Eyk JE, Bernstein KE. ACE overexpression in myeloid cells increases oxidative metabolism and cellular ATP. J Biol Chem. Jan 31;295(5):1369-1384 (2020).

13. Moore LG. Human genetic adaptation to high altitude. High Alt Med Biol 2001;2:257–279.

14. Wu TY, Li W, Li Y, et al. Epidemiology of chronic mountain sickness: Ten years study in Qingai-Tibet. In: Progress in Mountain Medicine and High Altitude Physiology (1998).

15. Peñaloza D, Sime F and Ruiz L. Corpulmonale in chronic mountain sickness: Present concept of Monge’s disease. In: High Altitude Physiology: Cardiac and Respiratory Aspects. Porter R. and Knight J, eds. Churchill Livingstone, Edinburgh 1971.

16. Leon-Velarde F and Richelet JP. Respiratory control in residents at high altitude: Physiology and pathophysiology. High Alt Med Biol 2016;7:125–137.

17. Plata R, Cornejo A, Arratia C, et al. Angiotensin-converting-enzyme inhibition therapy in altitude polycythaemia: A prospective randomised trial. Lancet 2002;359:663–666.

18. Kryger M, McCullough RE, Collins D, et al. Treatment of excessive polycythemia of high altitude with respiratory stimulant drugs. Am Rev Respir Dis 1978;117:455–464.

19. Villena M, Vargas E, Guenard H, et al. Double-blind study on the action of almitrine in patients with polycythemia of high altitude. Bull Eur Physiopathol Respir 1985;21:165–170.